EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Posttranslational modifications of phosphodiesterase type 4 enzymes represent novel points for therapeutic targeting

Madihah Hussain, Gonzalo S Tejeda, George S Baillie iD

The FEBS Journal · 2025

DOI: 10.1111/febs.70205 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The FEBS Journal, 2025. Verfasst von Madihah Hussain und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Cardiovascular and Metabolic Health, College of Medical Veterinary and Life Sciences, University of Glasgow, UK. Hauptthemen laut MEDLINE: Cyclic Nucleotide Phosphodiesterases, Type 4, Protein Processing, Post-Translational, Phosphodiesterase 4 Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, British Heart Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cyclic AMP is a second messenger that is produced in response to the activation of many G‐protein‐coupled receptors. As each receptor type is linked to a transient but distinct physiological outcome, the activation of cAMP effector proteins is highly compartmentalized by the action of phosphodiesterases (PDEs). Phosphodiesterase type 4 (PDE4) enzymes are expressed as 25 different isoforms, and the function of each protein is linked to its cellular location(s). Fine‐tuning of cAMP dynamics in space and time is underpinned by PDE4 activity shifts or PDE4 translocations that are driven by posttranslational modifications. As ‘omics’ technology improves, we are now learning more about these PDE4 events, and we can link them to diseases where aberrant cAMP signaling is causative. Additionally, recent advances allow us to pinpoint specific PDE4 modifications with targeted therapies that will lessen the chances of side effects. This review charts all known PDE4 modifications and links them to innovative existing pharmaceutical concepts or possible future therapeutic developments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cyclic Nucleotide Phosphodiesterases, Type 4Protein Processing, Post-TranslationalPhosphodiesterase 4 InhibitorsHumansCyclic AMPAnimalsSignal TransductionMolecular Targeted Therapy

Stichwörter der Autor:innen

cyclic AMPphosphodiesterase type 4posttranslational modification

Substanzen

Cyclic Nucleotide Phosphodiesterases, Type 4Cyclic AMPPhosphodiesterase 4 Inhibitors

Autor:innen und Institutionen

  • School of Cardiovascular and Metabolic Health, College of Medical Veterinary and Life Sciences, University of Glasgow, UK.

ORCID-Profile: George S Baillie

Förderung

  • Medical Research Council
  • British Heart Foundation

Zitieren

APA

Hussain, M., Tejeda, G. S., & Baillie, G. S. (2025). Posttranslational modifications of phosphodiesterase type 4 enzymes represent novel points for therapeutic targeting. The FEBS Journal. https://doi.org/10.1111/febs.70205

Vancouver

Hussain M, Tejeda GS, Baillie GS. Posttranslational modifications of phosphodiesterase type 4 enzymes represent novel points for therapeutic targeting. The FEBS Journal. 2025. doi:10.1111/febs.70205

BibTeX
@article{Hussain2025,
  author = {Hussain, Madihah and Tejeda, Gonzalo S and Baillie, George S},
  title = {Posttranslational modifications of phosphodiesterase type 4 enzymes represent novel points for therapeutic targeting},
  journal = {The FEBS Journal},
  year = {2025},
  doi = {10.1111/febs.70205}
}
Kostenlos starten →